News
27 drugmakers to provide generic COVID drug to low-income countries
Twenty-seven drug makers have signed onto a deal to manufacture a …
21588 items found
Patients
Chronic kidney disease: treating a silent killer
In November, NICE backed NHS use of AstraZeneca’s diabetes and heart …
Sales & Marketing
Content metrics help generate compelling communication
Companies seek efficiency and speed to market during the content …
News
Glenmark and Lotus partner on allergic rhinitis spray
The mission to treat people who suffer from allergic rhinitis has …
News
UK green lights Gilead Sciences, Galapagos ulcerative colitis drug
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has …
News
Gilead takes legal action against counterfeit HIV drug network
US pharma giant Gilead Sciences has accused a network of unauthorised …
News
Sugemalimab plus chemo boosts lung cancer survival, trial reveals
Lung cancer drug sugemalimab has delivered positive results following …
News
Endo, Florida reach $65M opioid settlement
Endo Pharmaceuticals and Endo Health Solutions, makers of Percocet, …
News
BioTuring enters collaboration to enable detailed single-cell RNA research
Research into single-cell sequencing has been boosted with Single …
News
Billionaire-backed "rejuvenation" start-up Altos Labs launches operations
Just months after the venture was unveiled, controversial …
News
Digital health companies enabling R&D topped 2021 US investment, Rock Health says
According to Rock Health's annual digital health funding report , …
Partner Content
Partner Content
6 critical success factors of a successful rapid first commercial launch
The success of any drug launch begins long before a regulatory agency …
Market Access
Policy in focus: Trump’s Most Favoured Nations drug pricing ...
Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Digital
Sponsored
Tracking studies get smarter: AI meets human intelligence
Having a continuous pulse on brand health is essential for pharmaceutical companies to inform strategic decisions and establish Key Performance Indicators (KPIs) in an ever-changing market
Market Access
12 questions with: Daniel Kohlstaedt
Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.
R&D
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Patients
FH25: Exploring the intersection of patients, HCPs, and tech...
In a new FH25 podcast, Denise Silber, founder of Basil Strategies and Doctors 2.0, discusses the intersection of HCPs, patients, and technology.
Oncology
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D
Partner Content
4th LNP Immunogenicity & Toxicity Summit
Assessing LNP Immunogenicity & Toxicity to Effectively Monitor Clinical Safety & Ensure Regulatory Compliance for Novel Therapeutics & Vaccines
R&D
Partner Content
7th Gene Therapy Analytical Development Summit | Leading AD ...
Advancing Analytics & QC from Pre-IND to BLA